Current Hypertension Reports

Current Hypertension Reports is an online-only review journal from Springer that commissions expert syntheses on the diagnosis, treatment, management and prevention of hypertension, publishing twelve issues a year with a 2025 Journal Impact Factor of 6.3.《当代高血压报告》（Current Hypertension Reports）是施普林格出版的全在线综述期刊，以约稿方式组织专家综合评述高血压的诊断、治疗、管理与预防，每年出版十二期，2025 年期刊影响因子为 6.3。

Scope

• Every article is a review rather than primary research, chosen to emphasise clinical findings published within roughly the previous two years.所有文章均为综述而非原创研究，选题侧重于近两年内发表的临床发现。
• Section Editors appointed for key subject areas, such as antihypertensive therapies, associated metabolic disorders and therapeutic trials, select the topics to be covered.期刊为各类关键主题聘任栏目编辑，例如降压治疗、相关代谢紊乱与治疗性试验，由他们选定拟刊主题。
• Leading experts then write comprehensive reviews that highlight new developments, supported by annotated reference lists that flag papers of major importance.随后由领域内领先专家撰写综合性综述，突出新进展，并配以带注释的参考文献表以标示重要论文。
• An international editorial board reviews the annual table of contents, proposes articles of regional interest and checks that topics remain current and include emerging research.国际编委会审阅年度目录，提出具有地区意义的选题，并核查主题是否保持前沿、是否涵盖新兴研究。
• Topical collections organise related reviews, including series on disparities in hypertension, hypertension and the brain, and guidelines and clinical trials.专题合集把相关综述组织成系列，包括高血压差异、高血压与脑、指南与临床试验等专题。
• The journal sits in the peripheral vascular disease category of the Science Citation Index Expanded and is indexed in MEDLINE, Scopus and EMBASE among other services.期刊归入科学引文索引扩展版的外周血管病类别，并被 MEDLINE、Scopus 与 EMBASE 等服务收录。

History

• The first volume appeared in 1999, and the title has reached volume 28 in 2026, published by Springer under its New York imprint.首卷于 1999 年问世，至 2026 年已出至第 28 卷，由施普林格在纽约的出版单元发行。
• It is now an online-only journal, and the print ISSN 1522-6417 has been formally ceased, leaving the electronic ISSN 1534-3111 in use.本刊现为全在线期刊，印刷版 ISSN 1522-6417 已正式停用，仅保留电子版 ISSN 1534-3111。
• The publishing model is hybrid, and 168 articles had been made open access by 2026, with more than half of 2025 output linked to the Sustainable Development Goals.出版模式为混合开放获取，截至 2026 年已有 168 篇开放获取文章，2025 年发表内容中逾半数与可持续发展目标相关。
• Springer reports a median of 12 days from submission to first decision, one of the faster turnaround figures among review journals in cardiology.施普林格公布从投稿到首次决定的中位时间为 12 天，在心脏病学综述期刊中属于较快的水平。
• Downloads reached 589,200 in 2025, and the impact factor rose from 4.592 in 2022 through 5.1 in 2024 to 6.3 in 2025.2025 年下载量达 589,200 次，影响因子从 2022 年的 4.592 经 2024 年的 5.1 升至 2025 年的 6.3。

Editors

• John E. Hall, PhD, MD, and Michael E. Hall, MD, MSc, share the editors-in-chief role, both working on cardiovascular and renal physiology.John E. Hall 与 Michael E. Hall 共同担任主编，两人的研究均集中于心血管与肾脏生理学。
• The section editor structure delegates topic selection to specialists in antihypertensive therapy, metabolic comorbidity and clinical trial design.栏目编辑制度把选题权下放给降压治疗、代谢共病与临床试验设计方面的专家。
• An international editorial board reviews the annual table of contents and advises on articles of special interest to particular countries and regions.国际编委会审阅年度目录，并就特定国家与地区特别关注的议题提供建议。
• Contributors are invited rather than drawn from open submission, a commissioning model typical of the Current Reports series at Springer.撰稿人以约稿为主而非公开征稿，这是施普林格当代报告系列常见的组稿模式。
• The editorial office operates from Springer's New York site, and correspondence and submission are handled through the Springer Nature platform.编辑部设于施普林格纽约站点，通信与投稿经施普林格·自然平台办理。